New Data From ENDEAVOR-II Challenges Conventional Wisdom on Drug-Eluting Stents

Medtronic News Release
19th May 2009




New clinical data presented today at a major international meeting of interventional cardiologists challenged the conventional wisdom on the long-term efficacy of drug-eluting stents, medical devices used in the treatment of coronary artery disease.

In ENDEAVOR-II (n=1,197), a randomized controlled trial comparing Medtronic’s (NYSE: MDT) Endeavor drug-eluting stent (DES) to its Driver bare-metal stent (BMS), patients treated with the Endeavor DES required fewer repeat procedures at five years post-implant than many observers and analysts would have expected based on the results of other trials with comparable designs.